在一项非对照多中心试验中,对可疑有全身性真菌感染的51例病人(年龄24天～17岁)给予氟康唑口服或静注治疗.27例证实了感染,其中26例通过真菌学检查,1例系组织学证实.所有分离的细胞属于念珠菌种.43例病人的临床评价为30例治愈,7例好转,6例无效.证实为真菌感染的27例中,25例采用真菌学评估,除1例外,其余均治愈.6例临床治疗无效的病人中,2例证实了感染,仅1例真菌学检查证实无效.由于有白色念珠菌和近平滑念球菌存在,将此患者初步诊断为原发性念珠菌菌血症.所有51例均评估其安全性.治疗结束后未发生与治疗有关的不良事件,仅有3例发生与治疗有关的副作用(腹泻、呕吐、耳聋),有3例发生与应用氟康唑治疗有关的实验室检查异常,包括肝酶水平和嗜酸性细胞计数升 In a non-controlled, multicenter trial, 51 patients (aged 24 days to 17 years) suspected of having systemic fungal infection were treated with oral or intravenous fluconazole.27 confirmed infection, of which 26 were infected with fungi One case was histologically confirmed, and all the isolated cells belonged to Candida species. The clinical evaluation of 43 patients was cured in 30, improved in 7, and ineffective in 6. Of the 27 patients confirmed to be fungal infections, 25 were used Mycology assessment, with the exception of one, was cured in all but six of the six patients who were ineffective in clinical treatment were confirmed as having an infection, only one of whom was found to be ineffective by mycological examination, due to the presence of Candida albicans and Candida parapsilosis, Patients were initially diagnosed with primary candidiasis and all 51 patients were evaluated for safety, no treatment-related adverse events occurred after the treatment, and only 3 patients had side effects associated with treatment (diarrhea, vomiting, deafness ) And 3 had laboratory abnormalities associated with fluconazole use, including liver enzyme levels and eosinophil counts